Developing vaccines is very hard work, as evidenced by Tuesday's news that AstraZeneca is pausing its clinical trials on a COVID-19 vaccine after a patient appeared to develop a serious neurological condition. And that raises an unsettling question: What if a vaccine is further away than most of us expect?
Axios Re:Cap digs in with Stat News reporter Adam Feuerstein, who helped break the AstraZeneca news.
On Tuesday's episode of "Axios on HBO," Mike Allen questioned Mark Zuckerberg about Facebook's content moderation policies before the November election — and what they're doing to stop the spread of misinformation.
Most Americans agree on the need for a safe and effective vaccine to protect us against COVID-19, but President Trump's repeated hints at a pre-election vaccine approval has sparked debate that politics could get ahead of the science.
Axios Re:Cap speaks with Zeke Emanuel, an Obama-era health policy official, about what he's looking for if and when a vaccine is approved.
It's increasingly evident that foreign actors, particularly Russia, are working to sow division in the country through disinformation. Much like the 2016 and 2018 election cycles, they're looking to exploit certain vulnerable issues among voters.
